Surrogate therapeutic endpoint for antiCTLA-4 based immunotherapy of disease

Details for Australian Patent Application No. 2004253865 (hide)

Owner Medarex, Inc.

Inventors Lowy, Israel; Nichol, Geoffrey M.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004253865

PCT Pub. Number WO2005/003298

Priority 60/475,067 30.05.03 US

Filing date 28 May 2004

Wipo publication date 13 January 2005

Acceptance publication date 23 June 2011

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

Event Publications

15 December 2005 PCT application entered the National Phase

  PCT publication WO2005/003298 Priority application(s): WO2005/003298

23 June 2011 Application Accepted

  Published as AU-B-2004253865

20 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253868-Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof

2004253863-MPTENs as modifiers of the PTEN/IGF pathway and methods of use